株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心房細動:世界の治験動向

Atrial Fibrillation Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 230761
出版日 ページ情報 英文 520 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
心房細動:世界の治験動向 Atrial Fibrillation Global Clinical Trials Review, H1, 2017
出版日: 2017年04月30日 ページ情報: 英文 520 Pages
概要

当レポートでは、心房細動に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7およびE7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数:心房細動治験件数の心臓血管治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:心房細動治験件数の心臓血管治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別治験件数

有望なスポンサー

治験主要参加企業 - 心房細動治療薬

有望な薬剤

最新治験ニュース:心房細動

治験プロファイルの基本情報

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's clinical trial report, "Atrial Fibrillation Global Clinical Trials Review, H1, 2017" provides an overview of Atrial Fibrillation clinical trials scenario. This report provides top line data relating to the clinical trials on Atrial Fibrillation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Atrial Fibrillation Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Atrial Fibrillation 30
  • Mar 31, 2017: Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation 30
  • Mar 19, 2017: Uninterrupted Pradaxa (dabigatran etexilate mesylate) Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation 30
  • Mar 17, 2017: Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation 31
  • Mar 13, 2017: Daiichi Sankyo Announces New Analyses of Once-Daily SAVAYSA (edoxaban) in Patients with Non-valvular Atrial Fibrillation to be Presented at the ACC 66th Annual Scientific Session 32
  • Mar 07, 2017: Daiichi Sankyo Initiates ENTRUST-AF PCI Study Investigating Once-Daily Lixiana (edoxaban) in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stenting 32
  • Feb 24, 2017: Real-World Data from Boehringer Ingelheim Show Lower Risk of Stroke and Major Bleeding for Pradaxa (dabigatran etexilate mesylate) Compared to Warfarin 33
  • Feb 13, 2017: Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral anti-arrhythmic budiodarone 33
  • Clinical Trial Profile Snapshots 35

Appendix 517

  • Abbreviations 517
  • Definitions 517
  • Research Methodology 518
  • Secondary Research 518
  • About GlobalData 519
  • Contact Us 519
  • Source 520

List of Tables

List of Tables

  • Atrial Fibrillation Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Atrial Fibrillation Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Atrial Fibrillation Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Atrial Fibrillation Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Atrial Fibrillation Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Atrial Fibrillation Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Atrial Fibrillation Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13
  • Atrial Fibrillation Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials, G7 Countries (%), 2017* 15
  • Atrial Fibrillation Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Atrial Fibrillation Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Atrial Fibrillation to Cardiovascular Clinical Trials, E7 Countries (%), 2017* 18
  • Atrial Fibrillation Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Atrial Fibrillation Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Atrial Fibrillation Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Atrial Fibrillation Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Atrial Fibrillation Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Atrial Fibrillation Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Atrial Fibrillation Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Atrial Fibrillation Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Atrial Fibrillation Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Atrial Fibrillation Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Atrial Fibrillation Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures

List of Figures

  • Atrial Fibrillation Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Atrial Fibrillation Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Atrial Fibrillation Therapeutics, Global, Clinical
Back to Top